Information Provided By:
Fly News Breaks for February 12, 2020
ARDX
Feb 12, 2020 | 05:53 EDT
Citi analyst Yigal Nochomovitz initiated coverage of Ardelyx with a Buy rating and $13 price target. The company is developing lead drug tenapanor for hyperphosphatemia in patients on dialysis, says the analyst, who expects a launch in mid-2021. Tenapanor will gain meaningful market share from phosphate binders in the hyperphosphatemia space, Nochomovitz tells investors in a research note. The analyst's bull case scenario is $22 per share for Ardelyx.
News For ARDX From the Last 2 Days
ARDX
Mar 26, 2024 | 14:26 EDT
Bullish option flow detected in Ardelyx with 3,829 calls trading, 1.1x expected, and implied vol increasing over 4 points to 96.18%. Apr-24 9 calls and 3/28 weekly 7.5 calls are the most active options, with total volume in those strikes near 2,300 contracts. The Put/Call Ratio is 0.13. Earnings are expected on May 1st.